Caxton Associates (UK)’s CorMedix CRMD Stock Holding History

Caxton Associates (UK)’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-53,310	Closed	-$620K	–	821
2025 Q4	$620K	Buy	+53,310	New	+$589K	0.01%	459

Other funds holding CRMD

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Caxton Associates (UK)'s CRMD Position: Q1 2026 in Review

Caxton Associates (UK) sold out of CorMedix (CRMD) in Q1 2026, closing a stake of 53,310 shares — an estimated $620K sold.

Caxton Associates (UK) first reported a position in CRMD in Q4 2025 and held it in 1 quarter. The position peaked at $620K in Q4 2025. 188 funds tracked by Wall St. Rank hold CRMD as of Q1 2026.

Caxton Associates (UK) reported no remaining CorMedix position as of Q1 2026 after selling out during the quarter.
Caxton Associates (UK) sold 53,310 CorMedix shares in Q1 2026, an estimated $620K.
Caxton Associates (UK) first reported a position in CorMedix in Q4 2025 and held it in 1 quarter.
Caxton Associates (UK)'s CorMedix position peaked at $620K in Q4 2025.
188 funds tracked by Wall St. Rank held CorMedix as of Q1 2026.

Based on Caxton Associates (UK)'s 13F filing for Q1 2026, filed 14 May 2026.